SECAUCUS, NJ - Quest Diagnostics (NYSE:DGX), a prominent provider of diagnostic information services, has announced the appointment of Robert B. Carter to its Board of Directors. Carter, who is currently the Executive Vice President and Chief Information Officer at FedEx Corporation (NYSE:FDX), will join the board following his retirement from FedEx.
Carter, 64, has had a distinguished 31-year career at FedEx, where he was responsible for the global technology infrastructure that supports the company's product offerings. His tenure at FedEx will conclude in June, after which he will serve as an advisor to the company until December.
Jim Davis, Chairman, CEO and President of Quest Diagnostics, expressed enthusiasm for Carter's (NYSE:CRI) appointment, citing his extensive leadership experience and expertise in cloud technologies and cybersecurity. Davis believes Carter's insights will be instrumental as Quest Diagnostics continues to integrate IT and generative AI to enhance its business operations.
Timothy M. Ring, Lead Independent Director, also remarked on the value Carter will bring to the board with his strong background in technology and his history of innovation and collaboration.
In addition to his role at FedEx, Carter has served on the boards of several other companies, including New York Life, and has a history of public and private board experience. He holds a bachelor's degree in computer and information science from the University of Florida and a master's degree from the University of South Florida.
Quest Diagnostics serves one in three adult Americans and half of the physicians and hospitals in the United States, providing diagnostic insights to improve health outcomes. The company's nearly 50,000 employees work to transform lives and contribute to a healthier world through their diagnostic insights.
This news is based on a press release statement from Quest Diagnostics.
In other recent news, Quest Diagnostics has been in the spotlight for several noteworthy developments. A study conducted by Haystack Oncology, a subsidiary of Quest Diagnostics, suggests that ctDNA testing for minimal residual disease could lower health plan costs by up to 21% for stage II colorectal cancer patients. Quest Diagnostics also announced the appointment of Robert B. Carter, the current Executive Vice President and Chief Information Officer at FedEx Corporation, to its Board of Directors, expanding the board's membership to 10.
Adding to these developments, Quest Diagnostics has declared a quarterly cash dividend of $0.75 per share, demonstrating its commitment to providing value to its shareholders. The company has also appointed Murali Balakumar as Senior Vice President and Chief Information and Digital Officer, a move expected to enhance the company's digital transformation efforts.
In a significant business move, Quest Diagnostics has acquired select assets from PathAI Diagnostics. This acquisition includes PathAI Diagnostics' digitized laboratory in Memphis, Tennessee, which will serve as Quest's hub for AI and digital R&D. The company will also license PathAI's AISight digital pathology image management system for use in its labs across the United States. These are recent developments that highlight Quest Diagnostics' commitment to integrating advanced technologies into its operations.
InvestingPro Insights
As Quest Diagnostics (NYSE:DGX) welcomes Robert B. Carter to its Board of Directors, investors and stakeholders may be interested in how the company is currently positioned in the market. According to InvestingPro data, Quest Diagnostics boasts a solid market capitalization of $15.65 billion. The company's commitment to shareholder returns is evident through its consistent dividend growth, having raised its dividend for 12 consecutive years and maintained dividend payments for 21 consecutive years—a testament to its financial stability and management's confidence in the company's future.
From a valuation standpoint, Quest Diagnostics trades at a P/E ratio of 18.66, reflecting investor confidence in the company's earnings potential. Additionally, the company's stock has been trading near its 52-week high, which indicates robust investor interest and a strong market presence. This aligns with the strategic expansion of the company's board, as it seeks to integrate advanced technologies to further its industry leadership.
InvestingPro Tips highlight that management has been aggressively buying back shares, a move that often signals a belief in undervalued stock and a commitment to enhancing shareholder value. Moreover, analysts predict that the company will be profitable this year, backed by a profitable performance over the last twelve months. For investors seeking detailed analysis and more of such strategic insights, InvestingPro offers additional tips on Quest Diagnostics, which can be accessed at https://www.investing.com/pro/DGX. Using the coupon code PRONEWS24, readers can get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, unlocking valuable metrics and tips that can inform investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.